Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
Verrica Pharmaceuticals Inc. (VRCA)
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. “It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. “Chris has an extraordinary track record of successfully commercializing several products in dermatology and other specialties, and has had success in building and leading commercial organizations in dynamic and competitive markets. I am confident that Chris’ commercial acumen will broaden access to YCANTH for molluscum patients and bring critical insights to our global Phase 3 program for common warts as well as the development of VP-315, our novel oncolytic peptide for basal cell carcinoma.” “I am excite
Show less
Read more
Impact Snapshot
Event Time:
VRCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRCA alerts
High impacting Verrica Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VRCA
News
- Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii PharmaceuticalGlobeNewswire
- Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VRCA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WallMarketBeat
- Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VRCA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
VRCA
Earnings
- 11/14/25 - Beat
VRCA
Sec Filings
- 2/2/26 - Form 3/A
- 1/29/26 - Form SCHEDULE
- 1/26/26 - Form 3
- VRCA's page on the SEC website